117087-18-0

Basic information

• Product Name: 2-[(benzyloxy)methyl]propane-1,3-diol
• Synonyms: 2-[(benzyloxy)methyl]propane-1,3-diol
• CAS NO: 117087-18-0
• Molecular Formula: C₁₁H₁₆O₃
• Molecular Weight: 196.24294
• Mol File: 117087-18-0.mol

Chemical Properties

• Boiling Point: 365.8±27.0 °C(Predicted)
• Appearance: /
• Density: 1.130±0.06 g/cm3(Predicted)
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: 14.27±0.10(Predicted)
• CAS DataBase Reference: 2-[(benzyloxy)methyl]propane-1,3-diol(CAS DataBase Reference)
• NIST Chemistry Reference: 2-[(benzyloxy)methyl]propane-1,3-diol(117087-18-0)
• EPA Substance Registry System: 2-[(benzyloxy)methyl]propane-1,3-diol(117087-18-0)

Safety Data

• Hazardous Substances Data: 117087-18-0(Hazardous Substances Data)

Usage

Physical state

Colorless to pale yellow liquid

Odor

Mild

Uses

Intermediate in the synthesis of pharmaceuticals, agrochemicals, and other organic compounds; building block in the production of polymers and resins

Hazards

Potentially hazardous substance, may cause irritation to skin, eyes, and respiratory system.

Upstream product

• 100-39-0 benzyl bromide 
• 125476-64-4 3-Benzyloxy-2-(hydroxymethyl)propionsaeure-ethylester 
• 117087-17-9 5-[(benzyloxy)methyl]-2,2-dimethyl-1,3-dioxane 
• 86008-12-0 2-isopropyl-5-benzyloxymethyl-1,3-dioxane 

Downstream Products

• 138435-91-3 (S)-3-(benzyloxy)-2-(hydroxymethyl)propyl acetate 
• 1394849-49-0 (S)-3-(benzyloxy)-2-[(mesyloxy)methyl]propyl acetate 
• 1394849-50-3 C₂₁H₂₁NO₅ 
• 1394849-51-4 (S)-3-(benzyloxy)-2-{[bis(tert-butoxycarbonyl)amino]-methyl}propyl acetate 
• 1394849-52-5 (S)-3-(benzyloxy)-2-({[tert-butyl(dimethyl)silyl]oxy}-methyl)propyl acetate 
• 1394849-53-6 (R)-3-(benzyloxy)-2-({[tert-butyl(dimethyl)silyl]oxy}-methyl)propan-1-ol 
• 1394849-54-7 (R)-3-(benzyloxy)-2-({[tert-butyl(dimethyl)silyl]oxy}-methyl)propyl methanesulfonate 
• 1394849-55-8 di-tert-butyl (R)-2-[3-(Benzyloxy)-2-({[tert-butyl-(dimethyl)silyl]oxy}methyl)propyl]-2-imidodicarbonate 
• 1394849-56-9 di-tert-butyl (S)-2-[3-(benzyloxy)-2-(hydroxymethyl)-propyl]-2-imidodicarbonate 
• 1394849-30-9 (R)-3-amino-2-[(benzyloxy)methyl]propan-1-ol monohydrochloride 
• 1394849-60-5 (S)-3-amino-2-[(benzyloxy)methyl]propan-1-ol monohydrochloride 
• 138435-88-8 3-Acetoxy-2-(acetoxymethyl)-1-(benzyloxy)propane 
• 1003013-76-0 3-((benzyloxy)methyl)oxetane 
• 1122410-38-1 methanesulfonic acid 2-benzyloxymethyl-3-methanesulfonyloxypropyl ester 

Relevant articles and documents

Preparation method of 3-oxetane carboxylic acid

The invention provides a preparation method of 3-oxetane carboxylic acid. The preparation method is characterized by carrying out hydrolytic esterification reaction, hydrogen pulling reaction and reduction reaction by taking 3-hydroxypropionitrile as a raw material, thus obtaining 2-benzyloxymethyl-1,3-propanediol; carrying out cyclization reaction, debenzylation reaction and oxidation reaction on2-benzyloxymethyl-1,3-propanediol, thus obtaining 3-oxetane carboxylic acid. According to the preparation method of 3-oxetane carboxylic acid, provided by the invention, a key intermediate 2-benzyloxymethyl-1,3-propanediol can be prepared just through three-steps reaction by taking 3-hydroxypropionitrile as the raw material, and 3-oxetane carboxylic acid can be prepared just through six-steps reaction in a final integral route, so that the reaction route is greatly shortened, and reaction steps are reduced; compared with a preparation method requiring ten-steps reaction in the prior art, theyield is higher, the operation is easy, and industrial production can be favorably realized.

MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS

Provided herein are antibacterial compounds, wherein the compounds in some embodiments have broad spectrum bioactivity. In various embodiments, the compounds act by inhibition of bacterial type 1 signal peptidase (SpsB), an essential protein in bacteria. Pharmaceutical compositions and methods for treatment using the compounds described herein are also provided.

MODULATORS OF SESTRIN-GATOR2 INTERACTION AND USES THEREOF

The present invention provides compounds, compositions thereof, and methods of using the same.

MODULATORS OF SESTRIN-GATOR2 INTERACTION AND USES THEREOF

The present invention provides compounds, compositions thereof, and methods of using the same.

Synthesis and evaluation of symmetric acyclic nucleoside bisphosphonates as inhibitors of the Plasmodium falciparum, Plasmodium vivax and human 6-oxopurine phosphoribosyltransferases and the antimalarial activity of their prodrugs

Two new series of symmetric acyclic nucleoside bisphosphonates (ANbPs) have been synthesised as potential inhibitors of the Plasmodium falciparum (Pf) and vivax (Pv) 6-oxopurine phosphoribosyltransferases. The structural variability between these symmetric ANbPs lies in the number of atoms in the two acyclic linkers connecting the N9 atom of the purine base to each of two phosphonate groups and the branching point of the acyclic moiety relative to the purine base, which occurs at either the alpha or beta positions. Within each series, six different 6-oxopurine bases have been attached. In general, the ANbPs with either guanine or hypoxanthine have lower Ki values than for those containing either the 8-bromo or 7-deaza 6-oxopurine bases. The lowest Ki values obtained for the two parasite enzymes were 0.1?μM (Pf) and 0.2?μM (Pv) for this series of compounds. Two phosphoramidate prodrugs of these inhibitors exhibited antimalarial activity against Pf in infected erythrocyte cell culture with IC50 values of 0.8 and 1.5?μM. These two compounds exhibited low cytotoxicity in human A549 cells having CC50 values of >300?μM resulting in an excellent selectivity index.

NUCLEOTIDE AND NUCLEOSIDE THERAPEUTICS COMPOSITIONS AND USES RELATED THERETO

This disclosure relates to nucleotide and nucleoside therapeutic compositions and uses in treating infectious diseases, viral infections, and cancer, where the base of the nucleotide or nucleoside contains at least one thiol, thione or thioether.

Development of a practical and scalable synthesis of (R)- and (S)-3-amino-2-[(benzyloxy)methyl]propan-1-ol monohydrochloride: A useful C-4 Chiral Building Block

The development of a practical and scalable synthesis of a C-4 chiral amine building block (R)-1·HCl and (S)-1·HCl is described. This important chiral intermediate (R)-1·HCl is efficiently synthesized from the commercially available, inexpensive, and simple 2-(hydroxymethyl)-1,3- propanediol (31) using lipase-catalyzed enantioselective hydrolysis as a key reaction. Development resulted in a telescoped process that was operated successfully and reproducibly in a pilot-plant-scale synthesis, and 22 kg of chiral amine (R)-1·HCl was prepared in the first scale-up synthesis. This synthetic method is also useful for preparation of the important chiral building block (S)-1·HCl, which is the enantiomer of (R)-1·HCl.

2-[2-Substituted-3-(3,4-dichlorobenzylamino)propylamino]-1H-quinolin-4-ones as Staphylococcus aureus methionyl-tRNA synthetase inhibitors

New analogues of 2-[2-substituted-3-(3,4-dichlorobenzylamino)propylamino]quinolin-4-ones, 26a, 26b, 31a-e, 34, 35, 38 and 40, have been synthesized and evaluated against Staphylococcus aureus methionyl-tRNA synthetase. All of the synthesized compounds were less active than the reference compound 2. The compounds were also screened against various strains of S. aureus and Enterococci for their antibacterial activities. Among the compounds, 26b, 31c and 31e displayed significant inhibitory properties against various strains of Enterococci compared to compound 2.

Pyrazole glucokinase activators

Disclosed herein are pyrazole glucokinase activators of the formula (I) useful for the treatment of metabolic diseases and disorders, preferably diabetes mellitus.

Bifunctional acyclic nucleoside phosphonates: 2. Symmetrical 2-{[bis(phosphono)methoxy]methyl}ethyl derivatives of purines and pyrimidines

Novel bisphosphonate alkylating agent, tetraisopropyl (2-[(mesyloxy)methyl] propane-1,3-diyl]bis(oxymethylene)bisphosphonate 19, was synthesized from diethyl 2,2-bis-(hydroxymethyl)malonate. Decarbethoxylation of the diethyl 2,2-dimethyl-1,3-dioxane-5,5-dicarboxylate was followed by chloromethylation of 2-[(benzyloxy)methyl]propane-1,3-diol and Arbuzov reaction with triisopropyl phosphite. Bisphosphonate building block 19 was used in the alkylation of various nucleobases (2-amino-6-chloropurine, adenine, 2-amino-6-(cyclopropyl) aminopurine, cytosine, uracil and 4-methoxy-5-methylpyrimidin-2(1H)-one). N 9-Substituted purines and N1-substituted pyrimidines were converted to appropriate free bisphosphonic acids. No antiviral or cytostatic activity was detected.